Tiefenbacher Group and Neuraxpharm announce the launch of Riulvy ® (Tegomil Fumarate) in Germany
Tiefenbacher Group and Neuraxpharm announce the launch of Riulvy® (Tegomil Fumarate) in Germany
At Tiefenbacher Group, we are deeply committed to developing and delivering high-quality, value-added pharmaceuticals that improve the lives of patients worldwide. In collaboration with our trusted partner Neuraxpharm we are proud to announce the successful launch of Riulvy ® (Tegomil Fumarate) 174 mg and 348 mg in Germany, which represents the first market introduction of this medicine in Europe.
About Riulvy®
Tegomil Fumarate is intended for the treatment of adults, children and adolescents aged 13 years and older with relapsing forms of Multiple Sclerosis (MS). The new product provides a therapy that maintains equivalent to existing fumarate treatments while offering a more favorable gastrointestinal tolerability profile *(1 & 2) and a practical daily dose of two capsules *(3).
Expanding access to Tegomil Fumarate
Around 2,8 million people worldwide *(4) live with MS, 280,000 of them in Germany *(5). After years of rigorous research, development, and regulatory efforts, the launch of Riulvy®, which is marketed by Neuraxpharm, marks an important step towards addressing unmet medical needs in the MS community. The successful development of the product is the result of close collaboration between Neuraxpharm and Tiefenbacher Group.
We would like to thank our colleagues for their hard work, which made this success possible, and we will continue to work on making advanced therapies more affordable, more available, and better tolerated for patients globally. That is why we look forward to expanding access to Tegomil Fumarate in further international markets in the near future.
Sources:
1. Data on file, Neuraxpharm. Bioavailability study.
2. Fonseca M, et al. (2025). A randomized, double-blind study to compare the gastrointestinal tolerability and safety following oral administration of tegomil fumarate versus an equimolar dose of dimethyl fumarate to healthy participants.
3. Technical information Riulvy (Aug. 2025)
4. Multiple Sclerosis International Federation – MS Atlas – 3rd edition (Sep. 2020) and European MS Platform (2020) MS Barometer.
5. msfp – Multiple Sklerose Forschungs- und Projektentwicklungs-gGmbH (Dez. 2024)
About Tiefenbacher Group – Pioneering Healthcare since 1963
Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From the initial idea to market access of high-quality medicines around the world: We distribute APIs and develop, produce, and register finished dosage forms (FDFs) including highly potent drugs as well as medical devices. Our purpose is to improve people’s lives by making pharmaceuticals more affordable, more available, and better than ever before.
For further information about TIEFENBACHER GROUP and our solutions for better healthcare and our in-house capabilities to develop and commercialize pharmaceutical products for global markets (including highly potent drugs) please contact us by email at info@tiefenbacher.com or visit us on: www.tiefenbachergroup.com
Tiefenbacher Group Career Stories No 3
"Get to know Badri Narayana, Quality Assurance Manager at Tiefenbacher Group!"
At TiefenbacherGroup, it’s our people who drive innovation, collaboration, and impact across the globe. That’s why we’re excited to share another story in our video series highlighting the individuals who make Tiefenbacher a unique place to work and grow.
In this episode
Badri talks about his experience joining Tiefenbacher’s InternationalExchange program, moving from Tiefenbacher Laboratories in India to our Hamburg office. He shares what makes this journey so special for him and how it has shaped his professional development.
“What makes this experience truly special is that Tiefenbacher gave me the opportunity to move from manufacturing in India to the Hamburg office to gain new experiences, and I felt genuinely welcomed and integrated into the team.” – Badri Narayana
Curious to learn more? Watch the video below and discover how international perspectives shape the culture at Tiefenbacher Group.
About Tiefenbacher Group – Pioneering Healthcare since 1963
Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From the initial idea to market access of high-quality medicines around the world: We distribute APIs and develop, produce, and register finished dosage forms (FDFs) including highly potent drugs as well as medical devices. Our purpose is to improve people’s lives by making pharmaceuticals more affordable, more available, and better than ever before.
For further information about TIEFENBACHER GROUP and our solutions for better healthcare and our in-house capabilities to develop and commercialize pharmaceutical products for global markets (including highly potent drugs) please contact us by email at info@tiefenbacher.com or visit us on: www.tiefenbachergroup.com
Tiefenbacher Group celebrates World Humanitarian Day
Tiefenbacher Group supports Humanitarian Aid in Ukraine
Today, on World Humanitarian Day, we honor the spirit of solidarity and the people who dedicate their lives to supporting communities in need.
This day was designated by the United Nations General Assembly to honor humanitarian workers around the world and raise awareness for humanitarian assistance. The World Humanitarian Day reminds us of the continuous pressure humanitarian systems face, especially under crises.
Our commitment to stand with humanitarian organizations
At Tiefenbacher Group, our culture of caring drives us to take responsibility beyond business. That’s why we are proud to support Apotheker ohne Grenzen Deutschland e.V. | Pharmacists without borders Germany, an NGO that provides emergency pharmaceutical aid and strengthens health systems worldwide.
Through our long-term partnership, we contribute to delivering vital medicines where they are needed most. For example, to children and families affected by the ongoing war in Ukraine. Together, we aim to make healthcare more accessible and improve lives, especially in times of crisis.
On this day, we reaffirm our commitment to stand with humanitarian organizations and encourage others to join in fostering a healthier, more humane world.
About Tiefenbacher Group – Pioneering Healthcare since 1963
Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From the initial idea to market access of high-quality medicines around the world: We distribute APIs and develop, produce, and register finished dosage forms (FDFs) including highly potent drugs as well as medical devices and e-health-solutions. Our purpose is to improve people’s lives by making pharmaceuticals more affordable, more available, and better than ever before.
For further information about our solutions for better healthcare and our in-house capabilities to develop and commercialize pharmaceutical products (including highly potent drugs) and e-health-solutions for global markets, please contact us by email at info@tiefenbacher.com or visit us on: www.tiefenbachergroup.com
Tiefenbacher Group Career Stories No 2
"Get to know Johanna Hansen, AI Project Manager at Tiefenbacher Group!"
At Tiefenbacher Group, it’s our people who shape innovation, company culture and our impact on patients around the world. That’s why we’re excited to continue our video series giving you a behind-the-scenes look at the individuals who make Tiefenbacher a unique place to work and grow.
In this episode
Johanna shares her journey from starting with Tiefenbacher as a dual student to gaining experience in multiple roles and departments over the years, leading to her current position as AI Project Manager.
“What truly motivates me is that Tiefenbacher invests in individual growth while making affordable medicines available. When you can see how the pharmacy projects you have worked on come to life and create a real impact for patients around the world, that’s amazing.” – Johanna Hansen
Curious to know more? Watch the video below and discover what makes Tiefenbacher Group a top choice for building your career.
About Tiefenbacher Group – Pioneering Healthcare since 1963
Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From the initial idea to market access of high-quality medicines around the world: We distribute APIs and develop, produce, and register finished dosage forms (FDFs) including highly potent drugs as well as medical devices. Our purpose is to improve people’s lives by making pharmaceuticals more affordable, more available, and better than ever before.
For further information about TIEFENBACHER GROUP and our solutions for better healthcare and our in-house capabilities to develop and commercialize pharmaceutical products for global markets (including highly potent drugs) please contact us by email at info@tiefenbacher.com or visit us on: www.tiefenbachergroup.com
Tiefenbacher Group Career Stories No 1
"Get to know Sayan Sarkar, Head of Global Digitalization & AI at Tiefenbacher Group!"
At Tiefenbacher Group, it’s our employees who shape innovation, company culture, and impact on patients around the world. That’s why we’re excited to launch a new video series giving you a behind-the-scenes look at the people working at Tiefenbacher.
In this episode
Sayan Head of Global Digitalization & AI shares what drives him, how he started his journey with us, and what makes working at Tiefenbacher Group so special.
“What motivates me to work here every day is the direct impact we create on people’s lives, especially where our products are the lifeline for many protected groups, e.g. children.”- Sayan Sarkar
Curious to know more? Watch the video below and discover what makes Tiefenbacher Group a unique place to grow.
About Tiefenbacher Group – Pioneering Healthcare since 1963
Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From the initial idea to market access of high-quality medicines around the world: We distribute APIs and develop, produce, and register finished dosage forms (FDFs) including highly potent drugs as well as medical devices. Our purpose is to improve people’s lives by making pharmaceuticals more affordable, more available, and better than ever before.
For further information about TIEFENBACHER GROUP and our solutions for better healthcare and our in-house capabilities to develop and commercialize pharmaceutical products for global markets (including highly potent drugs) please contact us by email at info@tiefenbacher.com or visit us on: www.tiefenbachergroup.com
Tiefenbacher New Market Launch: Buprenorphine Patches in South Africa
Tiefenbacher Pharmaceuticals successfully prepared the launch of the analgesic Buprenorphine as Transdermal Patch in South Africa.
We at Tiefenbacher Pharmaceuticals strongly believe that our high-quality medicines should be affordable and available for all patients around the world. That´s why we are thrilled to share that we have successfully prepared the launch of the generic version of the analgesic Buprenorphine as transdermal patch in South Africa.
Affordable Medicines are therapeutically equivalent to their branded counterparts with a lower price due to losing patent protection. The low costs of generic medications promote patient affordbility and contribute to lower per capita healthcare spendings.
Buprenorphine
is part of the opioid analgesics class and is used to help relieve severe, long-lasting pain – for example, caused by arthritis or chronic back conditions. To support patients with such conditions, our cooperation partner has marketed the transdermal patches in strengths of 5 mcg, 10 mcg, and 20 mcg. These have already been successfully launched in several international markets before.
The successful launch of this affordable medicine is a testament to the hard work and dedication of our team. We are particularly excited about the positive impact for the South African healthcare system and look already forward to further market entries of our high-quality medicines.
TIEFENBACHER PHARMACEUTICALS, a part of Tiefenbacher Group, develops and commercializes generic, value added, and innovative pharmaceuticals as well as medical devices and e-health-solutions worldwide. We provide over 180+ pharmaceutical products across various therapeutic categories in 10+ dosage forms. With our in-house product development and manufacturing, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines for global markets.
For more information about our finished dosage forms (FDF) including highly potent drugs and e-healthcare solutions, please contact us at info@tiefenbacher.com or visit us on www.tiefenbacher-pharmaceuticals.com
About Tiefenbacher Group – Pioneering Healthcare since 1963
Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company. We are providing best-in-class solutions along the entire pharmaceutical value chain. From the initial idea to market access of high-quality medicines around the world: We distribute APIs and develop, produce, and register finished dosage forms (FDFs) including highly potent drugs as well as medical devices and e-health solutions. The purpose is to improve people’s lives by making pharmaceuticals more affordable, more available, and better than ever before.
For further information about TIEFENBACHER GROUP please contact us by email at info@tiefenbacher.com or visit us on: www.tiefenbachergroup.com
Tiefenbacher Group Self-Care Day
At Tiefenbacher Group, we believe that a healthier workplace starts with healthier people.
That’s why we dedicated a full Self-Care Day to one of the most overlooked pillars of workplace well-being: spinal health. With the support of Dr. Subhadra Rani, we hosted a holistic Yoga session at Tiefenbacher Laboratories in Hyderabad focusing on preventive techniques for Sciatica and Spondylitis, which are two common conditions that affect mobility and energy levels, especially in sedentary work environments.
Through gentle stretches, awareness exercises, and breathing techniques, our colleagues were introduced to practical tools they can integrate into everyday life.
Why this matters?
- 75% of adults experience back pain at some point in their lives
- Regular movement and posture awareness can prevent chronic issues
- Mindful breaks during work reduce stress and increase focus
- Team-based activities promote a caring and connected workplace culture
We’re proud to support initiatives like these that bring science, movement, and community together.
About Tiefenbacher Group – Pioneering Healthcare since 1963
Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From the initial idea to market access of high-quality medicines around the world:
We distribute APIs and develop, produce, and register finished dosage forms (FDFs) including highly potent drugs as well as medical devices. The purpose is to improve people’s lives by making pharmaceuticals more affordable, more available, and better than ever before.
For further information about TIEFENBACHER GROUP and our solutions for better healthcare and our in-house capabilities to develop and commercialize pharmaceutical products for global markets (including highly potent drugs) please contact us by email at info@tiefenbacher.com or visit us on: www.tiefenbachergroup.com
Pioneering Healthcare at Tiefenbacher Group
Curiosity Driven, Excellence Focused, Patient Centered
At Tiefenbacher Group, we believe that our expertise must be leveraged for the greater good – to improve patients’ lives worldwide by pioneering healthcare. Our core values of being CURIOSITY DRIVEN, EXCELLENCE FOCUSED, and PATIENT CENTERED guide our actions and decisions every day. These values help us achieve our purpose of making high-quality pharmaceuticals more affordable, more available, and better than ever before.
But what does it mean to be “excellence focused”? We asked our TIEFENBACHER GROUP Managing Director, Dr. Kristian Ruepp, to elaborate:
How does Tiefenbacher Group’s commitment to being “Patient Centered” shape your approach to pharmaceutical development?
It starts with asking questions and then just listening – to patients, doctors, nurses, payers and many more stakeholders. When you then add a genuine curiosity to understand the challenges in the lives of patients and a motivation to challenge the status quo, then we always find great ideas for new development projects.
Can you provide examples of how Tiefenbacher ensures its products are accessible and affordable for patients, and why these aspects are essential to your mission?
In terms of accessibility we see many countries worldwide, in which highly important pharmaceuticals have never been launched by big pharma companies and patients therefore have no access to these therapeutic options. In many cases we are the first to launch such pharmaceuticals with our partners in such countries and provide access to these valuable drugs to patients.
Affordability of pharmaceuticals is a main driver behind generics or better affordable medicines. Without the savings, which off-patent, affordable medicines deliver to the societies, there would be no money left to fund new innovative drugs. At Tiefenbacher we are mainly driven by being the first to offer more affordable medicines and supplying the markets reliably at a highly competitive price.
With our development capabilities, our global supplier network and our manufacturing sites we are a driver to make medicines more affordable together with our marketing partners.
How does Tiefenbacher Group incorporate patient feedback and insights from healthcare professionals into its products and services?
One example comes into my mind with this question. Several years back, we heard from patients and doctors that a well-known pharmaceutical for treating a disease of the central nervous system causes severe gastro intestinal side effects for many patients in their life-long treatment. We understood that the reason for these side effects was based on the highly reactive chemical structure of this pharmaceutical substance.
We decided to develop a pro-drug to reduce these sides effects. Today we are very happy that we received the marketing authorization in Europe and could prove in a safety study that we reduce significantly these gastric side effects. Many patients will benefit from our idea and this pharmaceutical help patients live a healthier life.
At Tiefenbacher Group, the focus on excellence is the foundation of our pioneering approach to healthcare. We are excited about the future and remain committed to improving patients´ lives globally.
Feel free to reach out for more insights into our journey or to join us in pioneering the future of healthcare!
About Tiefenbacher Group – Pioneering Healthcare since 1963
Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From the initial idea to market access of high-quality medicines around the world: We distribute APIs and develop, produce, and register finished dosage forms (FDFs) including highly potent drugs as well as medical devices and e-health solutions. The purpose is to improve people’s lives by making pharmaceuticals more affordable, more available, and better than ever before.
For further information about TIEFENBACHER GROUP and our solutions for better healthcare and our in-house capabilities to develop and commercialize pharmaceutical products for global markets (including highly potent drugs) please contact us by email at info@tiefenbacher.com or visit us on: www.tiefenbachergroup.com
Tiefenbacher Group Hamburg Triathlon 2025
Tiefenbacher Group at Hamburg Triathlon 2025 crossing the finish line.
Last weekend, our team took on the challenge of the Hamburg Wasser World Triathlon 2025 right in the heart of Hamburg!
From the swim in the Alster to the bike ride through the city and the final push across the finish line, our colleagues showed true determination, endurance, and teamspirit.
The atmosphere was simply incredible
The Hamburg Triathlon has been a highlight in the global triathlon calendar since 2002 and is one of the world’s largest triathlon events, attracting over 10,000 athletes and 250,000 spectators each year. As part of the World Triathlon Championship Series, it brings together professionals and amateurs alike in an electric atmosphere that turns Hamburg into a festival of fitness and resilience.
We’re proud of everyone who participated and cheered along the sidelines. You’ve inspired us all!
About Tiefenbacher Group – Pioneering Healthcare since 1963
Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From the initial idea to market access of high-quality medicines around the world:
We distribute APIs and develop, produce, and register finished dosage forms (FDFs) including highly potent drugs as well as medical devices. The purpose is to improve people’s lives by making pharmaceuticals more affordable, more available, and better than ever before.
For further information about TIEFENBACHER GROUP and our solutions for better healthcare and our in-house capabilities to develop and commercialize pharmaceutical products for global markets (including highly potent drugs) please contact us by email at info@tiefenbacher.com or visit us on: www.tiefenbachergroup.com
Tiefenbacher Group about affordable medicines
Why are affordable medicines so important for healthcare?
Did you know that affordable (generic) medicines represent the majority of treatments in Europe, accounting for 70% of the treatment volume and 19% of the market value in 2023? They play a crucial role in ensuring patient well-being and public health by providing safe, effective, and affordable treatments. Without the competition created by affordable medicines, European healthcare payers would have had to spend an additional €120 billion in 2023 alone.*
IQVIA summarizes 4 value dimensions of affordable medicines:
Economic Value
- Support predictable and sustainable spending growth for healthcare systems
- Provide reliable future savings for payers
- Reduce co-payments for patients
Access
- Expand access to major chronic therapy areas
- Help to reduce disease burden in underserved markets
Supply Chain
- Mitigate the risk of shortages through multi-source supply
- 9 in 10 critical medicines are affordable medicines
Innovation
- Value added (affordable) medicines offer a range of unique benefits to patients
- Stimulate continued innovation from originators
At Tiefenbacher Group, we are proud to contribute to sustainable healthcare by developing and supplying high-quality affordable, valueadded, and innovative medicines. Our commitment goes beyond cost savings, it’s about making essential medicines accessible to more patients, ensuring treatment continuity, and fostering pharmaceutical innovation to improve patients`lives around the world.
*(Sources: IQVIA Beneath the Surface; OECD – OCDE Indicators Report; The Center for Biosimilars AAM Report; Medicines for Europe)
About Tiefenbacher Group – Pioneering Healthcare since 1963
Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From the initial idea to market access of high-quality medicines around the world: We distribute APIs and develop, produce, and register finished dosage forms (FDFs) including highly potent drugs as well as medical devices and e-health-solutions. Our purpose is to improve people’s lives by making pharmaceuticals more affordable, more available, and better than ever before.
For further information about our solutions for better healthcare and our in-house capabilities to develop and commercialize pharmaceutical products (including highly potent drugs) and e-health-solutions for global markets, please contact us by email at info@tiefenbacher.com or visit us on: www.tiefenbachergroup.com
